Aura Biosciences, Inc.
AURA
$7.00
$0.142.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.33% | -2.43% | -7.55% | -2.58% | 8.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.08% | -2.05% | 20.12% | 25.71% | 30.13% |
| Operating Income | -20.08% | 2.05% | -20.12% | -25.71% | -30.13% |
| Income Before Tax | -22.61% | 1.03% | -24.31% | -32.62% | -39.70% |
| Income Tax Expenses | -38.89% | -37.50% | -39.53% | -- | -60.87% |
| Earnings from Continuing Operations | -22.57% | 1.06% | -24.18% | -32.86% | -39.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.57% | 1.06% | -24.18% | -32.86% | -39.47% |
| EBIT | -20.08% | 2.05% | -20.12% | -25.71% | -30.13% |
| EBITDA | -20.35% | 2.00% | -20.54% | -26.18% | -30.61% |
| EPS Basic | 8.92% | 26.37% | 6.47% | -13.47% | -37.59% |
| Normalized Basic EPS | 8.88% | 26.35% | 6.39% | -13.29% | -37.79% |
| EPS Diluted | 8.92% | 26.37% | 6.47% | -13.47% | -37.59% |
| Normalized Diluted EPS | 8.88% | 26.35% | 6.39% | -13.29% | -37.79% |
| Average Basic Shares Outstanding | 34.56% | 34.37% | 32.77% | 17.09% | 1.36% |
| Average Diluted Shares Outstanding | 34.56% | 34.37% | 32.77% | 17.09% | 1.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |